1 | emax highly crosslinked polyethylene | | | | | | | 2 | 0.77% |
2 | sa standalone alif cage | | | | | | | 2 | 0.77% |
3 | tesera sa standalone alif | | | | | | | 2 | 0.77% |
4 | renovis spine product group | | | | | | | 1 | 0.38% |
5 | into a powerful tesera | | | | | | | 1 | 0.38% |
6 | standalone cervical interbody system | | | | | | | 1 | 0.38% |
7 | cervical interbody system combines | | | | | | | 1 | 0.38% |
8 | interbody system combines advanced | | | | | | | 1 | 0.38% |
9 | system combines advanced material | | | | | | | 1 | 0.38% |
10 | combines advanced material science | | | | | | | 1 | 0.38% |
11 | advanced material science and | | | | | | | 1 | 0.38% |
12 | revolutionary manufacturing process into | | | | | | | 1 | 0.38% |
13 | manufacturing process into a | | | | | | | 1 | 0.38% |
14 | process into a powerful | | | | | | | 1 | 0.38% |
15 | a powerful tesera sc | | | | | | | 1 | 0.38% |
16 | renovis knee product group | | | | | | | 1 | 0.38% |
17 | spine product group renovis | | | | | | | 1 | 0.38% |
18 | interbody system tesera sc | | | | | | | 1 | 0.38% |
19 | system tesera sc standalone | | | | | | | 1 | 0.38% |
20 | interbody system renovis hip | | | | | | | 1 | 0.38% |
21 | system renovis hip product | | | | | | | 1 | 0.38% |
22 | renovis hip product group | | | | | | | 1 | 0.38% |
23 | hip product group renovis | | | | | | | 1 | 0.38% |
24 | product group renovis knee | | | | | | | 1 | 0.38% |
25 | group renovis knee product | | | | | | | 1 | 0.38% |
26 | cervical interbody system tesera | | | | | | | 1 | 0.38% |
27 | tesera sc standalone cervical | | | | | | | 1 | 0.38% |
28 | group renovis trauma product | | | | | | | 1 | 0.38% |
29 | trabecular technology emax highly | | | | | | | 1 | 0.38% |
30 | trabecular technology designed and | | | | | | | 1 | 0.38% |
31 | technology designed and built | | | | | | | 1 | 0.38% |
32 | designed and built to | | | | | | | 1 | 0.38% |
33 | and built to promote | | | | | | | 1 | 0.38% |
34 | built to promote bone | | | | | | | 1 | 0.38% |
35 | ingrowth and longterm stability | | | | | | | 1 | 0.38% |
36 | and longterm stability tesera | | | | | | | 1 | 0.38% |
37 | longterm stability tesera trabecular | | | | | | | 1 | 0.38% |
38 | stability tesera trabecular technology | | | | | | | 1 | 0.38% |
39 | tesera trabecular technology tesera | | | | | | | 1 | 0.38% |
40 | technology emax highly crosslinked | | | | | | | 1 | 0.38% |